Pharmacielo Ltd
XTSX:PCLO

Watchlist Manager
Pharmacielo Ltd Logo
Pharmacielo Ltd
XTSX:PCLO
Watchlist
Price: 0.1 CAD 11.11%
Market Cap: CA$18.8m

Relative Value

PCLO doesn't have a meaningful market cap.

The Relative Value of one PCLO stock under the Base Case scenario is hidden CAD. Compared to the current market price of 0.1 CAD, Pharmacielo Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PCLO Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

PCLO Competitors Multiples
Pharmacielo Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Pharmacielo Ltd
XTSX:PCLO
18.8m CAD 6.7 -2.9 -4.8 -3.7
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.6 36.6 39.3
US
Johnson & Johnson
NYSE:JNJ
538.2B USD 5.7 20.1 14 17.2
CH
Roche Holding AG
SIX:ROG
279.1B CHF 4.5 29.5 12.5 14.6
UK
AstraZeneca PLC
LSE:AZN
214.8B GBP 5 31.1 20.2 29.6
CH
Novartis AG
SIX:NOVN
223.2B CHF 5 19.6 15.7 20.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.5 16.8 11.7 13.6
US
Merck & Co Inc
NYSE:MRK
267.5B USD 4.2 14.1 10 11.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
149.5B USD 2.4 15.3 7.7 10.6
FR
Sanofi SA
PAR:SAN
97.4B EUR 1.5 7.1 6.4 6.4
P/E Multiple
Earnings Growth PEG
CA
Pharmacielo Ltd
XTSX:PCLO
Average P/E: 23.1
Negative Multiple: -2.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.6
54%
1
US
Johnson & Johnson
NYSE:JNJ
20.1
6%
3.3
CH
Roche Holding AG
SIX:ROG
29.5
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.1
38%
0.8
CH
Novartis AG
SIX:NOVN
19.6
17%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
16.8
2%
8.4
US
Merck & Co Inc
NYSE:MRK
14.1
14%
1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.3
27%
0.6
FR
Sanofi SA
PAR:SAN
7.1
25%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Pharmacielo Ltd
XTSX:PCLO
Average EV/EBITDA: 48
Negative Multiple: -4.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.6
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
14
2%
7
CH
Roche Holding AG
SIX:ROG
12.5
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
20.2
10%
2
CH
Novartis AG
SIX:NOVN
15.7
6%
2.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.7
1%
11.7
US
Merck & Co Inc
NYSE:MRK
10
6%
1.7
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
0%
N/A
FR
Sanofi SA
PAR:SAN
6.4
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
Pharmacielo Ltd
XTSX:PCLO
Average EV/EBIT: 102.8
Negative Multiple: -3.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
37%
1.1
US
Johnson & Johnson
NYSE:JNJ
17.2
6%
2.9
CH
Roche Holding AG
SIX:ROG
14.6
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
29.6
23%
1.3
CH
Novartis AG
SIX:NOVN
20.3
12%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
13.6
0%
N/A
US
Merck & Co Inc
NYSE:MRK
11.8
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.6
7%
1.5
FR
Sanofi SA
PAR:SAN
6.4
15%
0.4